Pharmaceutical

Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

Sep 24, 2024 - 04:00
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Read the original article

Tags:

Previous Article

Pharmaceutical packaging machines and labelling companies

Next Article

Pancreatic cancer: The clinical trial landscape and progress for 2024 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Study finds supplements of amino acid taurine slow aging in mice and monkeys

STAT+: Study finds supplements of amino acid taurine sl...

Jun 8, 2023

Hipra’s Covid-19 booster gets EMA nod and enters an uncertain landscape

Hipra’s Covid-19 booster gets EMA nod and enters an unc...

Mar 31, 2023

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

Novavax seeks EMA approval for updated JN.1 Covid-19 va...

Jun 26, 2024